The payment card technology provider, which counts Visa, CommerzBank, CreditEase and Mastercard as investors, has added about $190m to close its IPO.

Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

GV and Novo-backed cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

Motif FoodWorks, launched by Gingko Bioworks, has pocketed $226m in a round backed by returning investor Louis Dreyfus a month after Gingko agreed to a reverse merger.

SoftBank Vision Fund 2 co-led a series B round for immunotherapy developer Umoja Biopharma with Cormorant Asset Management.

Propel Venture Partners has helped the retirement plan provider increase its overall funding to $344m by investing in a round led by General Atlantic.

The CreditEase-backed wealth management software provider was valued at $2bn after securing investment from D1 Capital Partners.

Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute, has picked up a series B co-led by SoftBank Vision Fund 2.

Motif FoodWorks, which traces its roots to MIT, has pocketed $226m in a round backed by returning investor Louis Dreyfus a month after Motif’s parent agreed to a reverse merger.

Shell Ventures has re-upped in G2 Venture Partners’ sophomore fund, which was also backed by Mitsui, Daimler and ABB Switzerland.